Mammography Facility Adverse Event and Action Report – March 5, 2024: Desert Imaging Services L.P.
Status of Facility
Desert Imaging Services, L.P. has a Texas Department of State Health Services (DSHS) mammography certificate in effect, is currently accredited and may provide mammography services.
Facility
Desert Imaging Services, L.P.
121 Paragon Lane
El Paso, TX 79912
Facility ID Number
227835
Inspection/Reporting Entity
State of Texas Certifying Agency (STX CA)
Actions Taken by the STX CA
Based on inspection findings and due to the serious image quality deficiencies noted during the Additional Mammography Review (AMR), the State of Texas Accreditation Body (STX AB) requested that the facility voluntarily suspend its mammography accreditation, and the facility agreed to the STX AB’s request. The facility underwent voluntary accreditation suspension effective February 15, 2023. The STX CA declared the mammography performed at this facility to be a serious risk to human health (SRHH), and the facility’s STX DSHS mammography certificate was placed into a “no longer in effect” status. The facility was required to perform a Patient and Referring Healthcare Provider Notification (PPN) to alert all at-risk patients and their healthcare providers of the mammography quality problems at the facility. The facility was also assessed state monetary penalties in the total amount of $18,041.
Corrective Action
The STX AB required the facility to submit and receive state approval for a Corrective Action Plan (CAP). The facility successfully completed the PPN requirement and was notified of such by the STX CA on August 14, 2023. The STX AB lifted the voluntary accreditation suspension, and the STX CA placed the facility’s certificate into effect on August 16, 2023. The facility is currently accredited and certified and may provide mammography services.
Background
The FDA compiles and makes available to physicians and the public information that is useful in evaluating the performance of mammography facilities. As of October 2010, the FDA posts individual notices following completion of the adverse actions taken against facilities. This information is useful in evaluating the performance of mammography facilities nationwide and assists providers and patients in making informed decisions. For additional information, please see the website at Reports (MQSA) | FDA
Additional Resources
For more information, please refer to the following web page: MQSA Program.